drugset
drugset / Trial / NCT04375514

Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis

NCT04375514 ↗

Phase 1/2 Terminated 43 enrolled Arrowhead Pharmaceuticals
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single doses of ARO-ENaC in healthy adult volunteers; and to evaluate the safety, tolerability, PK and efficacy of multiple doses of ARO-ENaC in patients with pulmonary cystic fibrosis.

Timeline

Start
2020-07-30
Primary completion
2021-05-09
Completion
2022-05-13

Outcome

Outcome not reported

Stopped (Business): “Business decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject ARO-ENaC Unknown 20 mg Inhaled
Subject ARO-ENaC Unknown 40 mg Inhaled
Subject ARO-ENaC Unknown 65 mg Inhaled
Subject ARO-ENaC Unknown 180 mg Inhaled

Indications

cystic fibrosis